May. 16 at 1:08 AM
$VXRT The Convergence: Everything Points to June
Seven Questions Keeping Sanofi's M&A Director Awake at Night
Somewhere inside Sanofi's corporate development office, the person running this deal is staring at seven threads that all terminate at the same moment — every one of them a pressure point he's never faced simultaneously in his career.
(1) How does he deal with what's coming when the target company's board unblinds, sees the actual Cohort 400 topline data his team has already reviewed, hands it to their banker — and realizes how insultingly low his offer was relative to what the data supports?
(2) How did 14 months of carefully constructed acquisition infrastructure — designed to be invisible to the market — end up so legible that amateur investors on stock message boards are reading the entire strategy like a comic book?
(3) Why is his government customer sitting in silence after publishing and then deactivating procurement documentation that only his post-acquisition entity can fulfill?
(4) How does he present his board a defensible offer for a stock trading at
$0.70 when the banker on the other side is likely to come back with a valuation north of
$37 per share — potentially higher once they incorporate the data his team has already seen?
(5) Why is the person sitting across the table — a director with more contested M&A experience than anyone in Sanofi's entire corporate development organization — someone who has been through fights his team has only read about in case studies?
(6) Why is Vaxart's General Counsel refusing to schedule an annual meeting positioned to replace Lo and two other board members — saying only "in due course" — unless he knows this deal makes that meeting irrelevant?
(7) And why does every thread — clinical, corporate, governmental, contractual — converge on June 30, 2026, the date after which his negotiating position collapses?
This is a trilateral negotiation where the US government holds more leverage than either the buyer or the seller. He's racing a clock he didn't set, playing chess on a board where the government controls half the pieces, and negotiating with a fuse burning under the table.
Thread 1: The Data Commitment
============================
On May 8, Vaxart committed to unblinding topline Cohort 400 data by June 30. His team has already reviewed this data through Sanofi's access.
Vaxart's board received his offer. Now they're arming their banker with the same data his team used to justify it.
The banker's valuation range was built without Cohort 400 results. Once the banker sees the data, that range moves up.
Beidmeyer will come back with a data-supported counter higher than the number on the table. The information advantage that gave Sanofi pricing leverage is about to evaporate.
Thread 2: The Exclusivity Cliff
=========================
Exclusivity and no-shop provisions appear to expire around June 30.
Today: He's the only bidder. Management is blinded. The stock is
$0.70. He controls the pace.
July 1: Positive data is public. Stock has repriced. Exclusivity is gone. Every large pharma with a vaccine portfolio is looking at a validated oral platform with
$453M in BARDA contract ceiling.
Every dollar he refuses to pay Beidmeyer now is a dollar he pays back tenfold in July — if he gets the platform at all.
Thread 3: The Annual Meeting Threat
===============================
Three hostile nominees. A vote positioned to replace Lo and two other board members. Berg saying "in due course."
Berg's "in due course" is consistent with a deal expected to preempt the meeting.
But if negotiations drag, the M&A director loses his known counterparties and starts over with a reconstituted board that owes him nothing.
Thread 4: BARDA's Next-Gen Vaccine Platform (NVP) Program
===================================================
His government customer is sitting in silence. Silence is a signal — it keeps pressure on Sanofi without committing BARDA to anything publicly.
BARDA published NVP market research March 26. Deactivated it April 30. Based on the sequence of public actions, this may have built sole-source procurement documentation, confirming no single-company alternative exists.
The NVP contract — potentially hundreds of millions across six threat targets — would justify the acquisition price to his board.
But BARDA's behavior suggests they won't confirm economics until after closing. He believes his board won't sign without those economics. A circular dependency — and a significant risk.
Thread 5: The Only Qualifying Solution
=================================
Based on publicly documented Special Notices, BARDA rejected Sanofi Pasteur's own platforms. Refused the partnership workaround — twice. Stated preference for a single-company solution.
The interpretation that fits the pattern most cleanly: Sanofi's path back into BARDA's biodefense portfolio runs through this acquisition.
If he fails, Sanofi loses NVP and watches whoever acquires VAAST capture the program Sanofi was positioned to win.
Thread 6: The Price Disparity
=========================
Vaxart trades at
$0.70. The independent banker is likely to come back with a valuation in the neighborhood of
$37 per share — climbing once Cohort 400 data is incorporated.
This isn't hype — it's the output of the four methodologies every independent banker uses: Public Comps, Precedent Transactions, DCF/Probability-Adjusted NPV, and Sum-of-the-Parts.
All four produced a blended range in the mid-30s before clinical data. Delaware courts rely on these same methodologies when market price is unreliable — exactly the case here.
The solve is standard: low upfront cash, high contingent value rights. Upfront cash of
$9-
$17/share covers platform IP, BARDA relationships, and contract infrastructure.
The remainder —
$28-
$41/share in CVRs — triggers only if government-funded milestones are achieved. CVR payments self-fund through NVP revenue. Risk stays with performance.
But Beidmeyer knows everything the M&A director knows — and is about to have data that pushes the range higher.
Thread 7: "In Due Course"
======================
Berg's two words suggest a deal is expected. A tender offer bypasses the annual meeting entirely — no election, no proxy fight. The CSG's nominees become irrelevant not because they lost a vote, but because the vote never happens. Beidmeyer appears to be closing, not browsing.
What Happens If He Doesn't Close
---------------------------------------------
Sanofi: Fourteen months of positioning becomes sunk cost. BARDA prefers Sanofi. BARDA doesn't need Sanofi.
Vaxart: Open bidding with
$61M cash, near-shell status, hostile slate positioned to replace management.
BARDA: FY2027 NVP dead. Earliest recovery FY2028.
$218.9M investment trapped. Multi-year biopreparedness gap.
His career: He let it slip because he couldn't close a price gap with a company trading at
$0.70.
Why BARDA's Incentives Align
=========================
On Sanofi: NVP value flows only if the acquisition closes while the sole-source pathway is current.
On Vaxart: Stop work orders proved standalone is precarious. Bayh-Dole march-in rights and §1498 give BARDA tools to route around Vaxart entirely.
The bridge: Sanofi's cost is subsidized by the contract waiting post-close. CVR milestones are far more likely to trigger inside Sanofi with government funding than standalone.
How It Plays Out
==============
Now–late May: Unblinding in progress. Banker receiving data. Beidmeyer formulating counter.
Late May–mid-June: Final negotiation. Cash vs. CVR allocation. Break fees.
Mid-June window: Agreement announced. Tender offer launched. Berg never schedules the annual meeting.
Early July window: Tender closes. Back-end merger sweeps remaining shareholders.
July–August window: BARDA executes NVP directed award to Sanofi as new platform owner.
October 1: FY2027 begins with NVP programmed and funded.
The Angst
=========
He's run dozens of acquisitions. None prepared him for this.
He's across from a deal fighter dismantling his position pressure point by pressure point.
Dependent on a government agency that won't confirm economics until after closing.
Defending a 50x premium to a board that evaluates optics as much as strategy.
Watching the target unblind data that will expose how low his initial offer was.
And what was supposed to remain invisible until announcement day increasingly appears legible to the market.
Retail traders on Stocktwits are mapping the architecture in real time. That was never supposed to happen.
All signals point to June. Beidmeyer knows it. BARDA knows it. Retail is figuring it out.
By July, either this entire framework collapses — or the market finally understands why every thread converged on June.
